Abstract
Alternative treatments from plant-derived small molecules for neutralizing the venom lethality in snake envenomation are prevalent now. Elephantopus scaber, a tropical plant species has been recognized for its various pharmacological activities and especially anti-snake venom property; however, the molecular basis for this property is not understood. It is reported that snake venom PLA2 is a toxic factor with pharmacological effects independent of their catalytic activity. Here we report the inhibition of catalytic property of Cobra and Viper (group I and group II) snake venom PLA2 by the phytocompounds from E. scaber through molecular docking and dynamics studies. Initially, Lipinski’s rule, ADMET, and molecular docking studies were carried out. Our results show that among 124 phytocompounds, crepiside E (deacylcynaropicrin-3′ beta-glucopyranoside) has shown interactions with the conserved catalytic active site residues, His 48 and Asp 49, in both the PLA2s. Further, molecular dynamic simulations for 60 ns confirmed the stability of crepiside E in the active site of PLA2s and were found to be stable throughout the simulation. In order to understand the drug-likeness of crepiside E, pIC50 and MMGBSA scores were correlated by performing a linear regression analysis. Crepiside E was found to have similar chemical features to that of doxycycline, a known PLA2 inhibitor as indicated by a similarity score of 64.15%. Hence, it is concluded that crepiside E beta glucopyranoside present in Elephantopus scaber contributes to neutralizing the snake venom.
Similar content being viewed by others
References
Mukherjee AK (2012) Green medicine as a harmonizing tool to antivenom therapy for the clinical management of snakebite: the road ahead. Indian J Med Res 136(1):10
Sakthivel G, Dey A, Nongalleima K, Chavali M, Rimal Isaac RS, Singh NS, Deb L (2013) In vitro and in vivo evaluation of polyherbal formulation against Russell’s viper and cobra venom and screening of bioactive components by docking studies. Evid Based Complement Alternat Med 2013:781216
Koh DCI, Armugam A, Jeyaseelan K (2006) Snake venom components and their applications in biomedicine. Cell Mol Life Sci 63(24):3030–3041
de Lima DC, Alvarez Abreu P, de Freitas CC, Santos DO, Borges RO, dos Santos TC, Mendes Cabral L, Rodrigues CR, Castro HC (2005) Snake venom: any clue for antibiotics and CAM? Evid Based Complement Alternat Med 2(1):39–47
Alam JM, Qasim RASHIDA, Alam SM (1996) Enzymatic activities of some snake venoms from families Elapidae and Viperidae. Pak J Pharm Sci 9(1):37–41
Bougis PE, Marchot P, Rochat H (1986) Characterization of Elapidae snake venom components using optimized reverse-phase high-performance liquid chromatographic conditions and screening assays for alpha-neurotoxin and phospholipase A2 activities. Biochemistry 25(22):7235–7243
Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A 2 enzymes: classification and characterization. Biochim Biophys Acta Mol Cell Biol Lipids 1488(1):1–19
Faure G, Xu H, Saul F (2010) Anticoagulant phospholipases A2 which bind to the specific soluble receptor coagulation factor Xa. Toxins and hemostasis. Springer, Dordrecht, pp 201–217
Schaloske RH, Dennis EA (2006) The phospholipase A 2 superfamily and its group numbering system. Biochim Biophys Acta Mol Cell Biol Lipids 1761(11):1246–1259
Warrell DA (1989) Snake venoms in science and clinical medicine 1. Russell’s viper: biology, venom and treatment of bites. Trans R Soc Trop Med Hyg 83(6):732–740
Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G (2011) Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 111(10):6130–6185
Kini RM, Clemetson KJ, Markland FS, McLane MA, Morita T (2010) Toxins and hemostasis: from bench to bedside. Springer, Dordrecht, p 600
Segelke BW, Nguyen D, Chee R, Xuong NH, Dennis EA (1998) Structures of two novel crystal forms of Naja naja naja phospholipase A 2 lacking Ca 2+ reveal trimeric packing. J Mol Biol 279(1):223–232
XingDing Z, Kini RM, Doley R, Mackessy SP (2009) Snake venom phospholipase A2 enzymes. Handbook of venoms and toxins of reptiles. Taylor and Francis, Boca Raton, pp 173–215
Singh G, Gourinath S, Saravanan K, Sharma S, Bhanumathi S, Betzel C, Srinivasan A, Singh TP (2005) Sequence-induced trimerization of phospholipase A2: structure of a trimeric isoform of PLA2 from common krait (Bungarus caeruleus) at 2.5 Å resolution. Acta Crystallogr Sect F: Struct Biol Cryst Commun 61(1):8–13
Kini RM (2005) Structure–function relationships and mechanism of anticoagulant phospholipase A 2 enzymes from snake venoms. Toxicon 45(8):1147–1161
Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50(Supplement):S237–S242
Pore SM, Ramanand SJ, Patil PT, Gore AD, Pawar MP, Gaidhankar SL, Ghanghas RR (2015) A retrospective study of use of polyvalent anti-snake venom and risk factors for mortality from snake bite in a tertiary care setting. Indian J Pharm 47(3):270
Pereañez JA, Patiño AC, Núñez V, Osorio E (2014) The biflavonoid morelloflavone inhibits the enzymatic and biological activities of a snake venom phospholipase A 2. Chem Biol Interact 220:94–101
Sivaramakrishnan V, Ilamathi M, Ghosh KS, Sathish S, Gowda TV, Vishwanath BS, Rangappa KS, Dhananjaya BL (2016) Virtual analysis of structurally diverse synthetic analogs as inhibitors of snake venom secretory phospholipase A2. J Mol Recognit 29(1):22–32
Sankar V, Kalirajan R, Sales FSV, Raghuraman S (2001) Anti inflammatory activity of Elephantopus scaber in albino rats. Indian J Pharm Sci 63(6):523
Sheeba KO, Wills PJ, Latha BK, Rajalekshmy R, Latha MS (2012) Antioxidant and antihepatotoxic efficacy of methanolic extract of Elephantopus scaber Linn in Wistar rats. Asian Pac J Trop Dis 2:S904–S908
Geng HW, Zhang XL, Wang GC, Yang XX, Wu X, Wang YF, Ye WC, Li YL (2011) Antiviral dicaffeoyl derivatives from Elephantopus scaber. J Asian Nat Prod Res 13(7):665–669
Bhusan SH, Ranjan SS, Subhangankar N, Rakesh S, Amrita B (2012) Nephroprotective activity of ethanolic extract of Elephantopus scaber leaves on albino rats. Int Res J Pharm 3:246–250
Rao G, Rao YV, Pavani S, Dasari VP (2012) Qualitative and quantitative phytochemical screening and in vitro anti oxidant and anti microbial activities of Elephantopus scaber Linn. Recent Res Sci Technol 4(4):15–20
Sagar R, Sahoo HB (2012) Evaluation of antiasthmatic activity of ethanolic extract of Elephantopus scaber L. leaves. Indian J Pharm 44(3):398
Aabid K, Arun P, Mukesh P, Singh BP (2011) Evaluation of anthelmintic property of alcoholic and aqueous extract of leaves of a Elephantopus scaber Linn. Int J Pharm Life Sci 2(2):551–553
Yan GR, Tan Z, Wang Y, Xu ML, Yu G, Li Y, He QY (2013) Quantitative proteomics characterization on the antitumor effects of isodeoxyelephantopin against nasopharyngeal carcinoma. Proteomics 13(21):3222–3232
Daisy P, Rayan NA, Rajathi D (2007) Hypoglycemic and other related effects of Elephantopus scaber extracts on alloxan induced diabetic rats. J Biol Sci 7(2):433–437
Mors WB, Do Nascimento MC, Pereira BMR, Pereira NA (2000) Plant natural products active against snake bite—the molecular approach. Phytochemistry 55(6):627–642
Sandeep VB, Dilip KJ (2012) Profile of medicinal plants with anti ophidian property. J Pharm Sci Innov 5:13–20
Ho WY, Ky H, Yeap SK, Rahim RA, Omar AR, Ho CL, Alitheen NB (2009) Traditional practice, bioactivities and commercialization potential of Elephantopus scaber Linn. J Med Plant Res 3(13):1212–1221
ACD/Structure Elucidator (2012) 2012 Free version. Advanced Chemistry Development, Inc., Toronto. www.acdlabs.com
Schrödinger Release 2015-3 (2015) LigPrep, version 3, vol 5. Schrödinger, LLC, New York
Small-Molecule Drug Discovery Suite 2016-3 (2016) QikProp, version 3.2. Schrödinger, LLC, New York
Accelrys Software Inc. (2007) Discovery studio modeling environment. Accelrys Software Inc., San Diego
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235–242. URL: www.rcsb.org/pdb
Schrödinger L (2010) PyMOL: the PyMOL molecular graphics system
Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221–234
Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, Repasky MP, Zhang LY, Berne BJ, Friesner RA, Gallicchio E, Levy RM (2005) Integrated modeling program, applied chemical theory (IMPACT). J Comput Chem 26(16):1752–1780
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 49(21):6177–6196
Sirin S, Kumar R, Martinez C, Karmilowicz MJ, Ghosh P, Abramov YA, Sherman W (2014) A computational approach to enzyme design: predicting ω-aminotransferase catalytic activity using docking and MM-GBSA scoring. J Chem Inf Model 54(8):2334–2346
Berendsen HJ, van der Spoel D, van Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 91(1-3):43–56
Ebrahimi, Mohsen, et al. (2018) Structural Insight into Binding Mode of 9-Hydroxy Aristolochic Acid, Diclofenac and Indomethacin to PLA 2. Interdisciplinary Sciences: Computational Life Sciences 10(2):400–410
Hess B, Bekker H, Berendsen HJ, Fraaije JG (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18(12):1463–1472
Maffucci I, Contini A (2013) Explicit ligand hydration shells improve the correlation between MM-PB/GBSA binding energies and experimental activities. J Chem Theory Comput 9(6):2706–2717
Srivastava HK, Sastry GN (2012) Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches. J Chem Inf Model 52(11):3088–3098
Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S, Rivara S, Barocelli E, Mor M, Lodola A (2013) Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem 56(7):2936–2947
Durante F (2014) The R book, second edition by Michael J. Crawley. Int Stat Rev 82:145–146. https://doi.org/10.1111/insr.12051_5
Placzek S, Schomburg I, Chang A, Jeske L, Ulbrich M, Tillack J, Schomburg D (2017) BRENDA in 2017: new perspectives and new tools in BRENDA. Nucleic Acids Res 45(D1):D380–D388
Selvaraj, Chandrabose, et al (2011) Tool development for Prediction of pIC 50 values from the IC 50 values-A pIC 50 value calculator. Current Trends in Biotechnology & Pharmacy 5(2):1104–1109
Yang LC, Wang F, Liu M (1998) A study of an endothelin antagonist from a Chinese anti-snake venom medicinal herb. J Cardiovasc Pharmacol 31:S249–S250
Halgren T (2007) New method for fast and accurate binding site identification and analysis. Chem Biol Drug Des 69(2):146–148
Marcussi S, Sant’Ana CD, Oliveira CZ, Quintero Rueda A, Menaldo DL, Beleboni RO, Stabeli RG, Giglio JR, Fontes M, Marcos R, Soares AM (2007) Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. Curr Top Med Chem 7(8):743–756
Pruzanski W, Greenwald RA, Street LP, Lauberte F, Stefanski E, Vadas P (1992) Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 44(6):1165–1170
Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, Tropsha A (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17(2-4):241–253
Kuca K, Musilek K, Jun D, Zdarova-Karasova J, Nepovimova E, Soukup O, Hrabinova M, Mikler J, TCC F, EFF DC, De Castro AA, Valis M, Ramalho TC (2018) A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase. BMC Pharmacol Toxicol 19(1):8
de Lima WEA, Pereira AF, de Castro AA, da Cunha EFF, Ramalho TC (2016) Flexibility in the molecular design of acetylcholinesterase reactivators: probing representative conformations by chemometric techniques and docking/QM calculations. Lett Drug Des Discov 13(5):360–371
Ojeda P, Ramírez D, Alzate-Morales J, Caballero J, Kaas Q, González W (2018) Computational studies of snake venom toxins. Toxins 10(1):8
da Silva Gonçalves A, França TCC, Caetano MS, Ramalho TC (2014) Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: reducing the computational cost in hybrid QM/MM methods. J Biomol Struct Dyn 32(2):301–307
Sales TA, Marcussi S, da Cunha EF, Kuca K, Ramalho TC (2017) Can inhibitors of snake venom phospholipases A2 lead to new insights into anti-inflammatory therapy in humans? A theoretical study. Toxins 9(11):341
Acknowledgements
This work was supported by the Centre for Excellence in Ayur-Informatics and Computer Aided Drug Design through FAST Scheme under MHRD (No. F. 5-6/2013-TS.VII) is gratefully acknowledged. The computational facilities were provided by the Department of Computational Biology and Bioinformatics, University of Kerala is also acknowledged. The authors would also like to sincerely thank Saraswathy V., Research Scholar, Department of Computational Biology and Bioinformatics, University of Kerala for her valuable suggestions and comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kumar, M.S., R., A., Bhaskaran, S. et al. Molecular docking and dynamic studies of crepiside E beta glucopyranoside as an inhibitor of snake venom PLA2. J Mol Model 25, 88 (2019). https://doi.org/10.1007/s00894-019-3954-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-019-3954-2